Customer concentration
A small number of customers account for a meaningful share of revenue, so lost orders can quickly reduce sales.
- Scope
- PrognomiQ and other early commercial accounts
- Materiality
- high
Seer, Inc.
Seer, Inc. develops the Proteograph Product Suite, a life sciences platform used to prepare and analyze proteins for deep proteomics research. The company is based in Redwood City, California and sells instruments, consumables, and related services to research and commercial customers in North America, Europe, and Asia Pacific.
−439,6 %
51,1 %
−444,0 %
+17,0 %
12.84
12.35
| % | |
|---|---|
| Instruments | 30% Proteograph-enabled automation and instrument systems used to run the workflow. |
| Consumables | 45% Assay kits, nanoparticles, reagents, and related workflow consumables. |
| Services | 20% Fee-for-service proteomic data generation, analysis, and access programs. |
| Other revenue | 5% Shipping revenue, lease arrangements, and related-party activity. |
Seer sells primarily to commercial companies, academic institutions, and other research organizations that need...
- Commercial life sciences companiesprimary
Buy Proteograph instruments, consumables, and services to support internal R&D and biomarker discovery.
- Academic and research institutionsprimary
Use the platform for population-scale and translational proteomics studies funded by grants.
- Fee-for-service userssecondary
Access Proteograph workflows through STAC when they want data without owning the system.
- Strategic and related-party accountssecondary
Buy products and services through collaboration or related-party arrangements such as PrognomiQ.
Seer is headquartered in the United States and generates most of its revenue domestically...
- •Headquartered in Redwood City, California
- •Revenue is primarily generated in the United States
- •Direct sales coverage in North America, the UK, EU, and APAC
- •STAC service center opened in Bonn, Germany
- •International growth depends on channel partners and local support
- •Consumables logistics matter because products can be temperature controlled
Seer’s strategy is to broaden adoption of Proteograph by lowering access barriers and expanding the number of ways...
01
Expand commercial adoption of Proteographshort-term
The business depends on converting scientific interest into recurring product and service usage.
02
Lower customer adoption barriersshort-term
Reducing capex and workflow friction can accelerate trial and repeat usage.
03
Scale manufacturing and supply chain capacitymedium-term
Broader availability requires reliable production of consumables and instruments.
04
Expand international presencemedium-term
International markets can diversify demand and broaden the installed base.
Seer is an early-stage commercial life sciences company with concentrated customers, limited operating history, and...
Dependence on research funding
Customers often rely on government or grant funding, so lower R&D budgets can reduce demand.
- Scope
- Academic and research institutions
- Materiality
- high
Commercialization execution
The company must build market acceptance for a specialized proteomics platform.
- Scope
- Sales, marketing, customer support, and channel expansion
- Materiality
- high
Supply chain and manufacturing disruption
Instruments and consumables rely on third-party manufacturing and sourced components.
- Scope
- Hamilton-made SP200 instruments and outsourced inputs
- Materiality
- medium
Intellectual property litigation
Proteomics tools can face infringement claims that affect product availability and cost.
- Scope
- Platform technology and assay workflow
- Materiality
- medium
Revenue recognition
Can shift revenue between periods and between product and service lines
Related-party transactions
Can affect concentration analysis and comparability
Lease and placement programs
Can change revenue timing and asset classification
Inventory and manufacturing estimates
Can affect gross margin and inventory carrying values
Fair value of investments
Can create volatility outside core operating performance
: 29.4.2026